Second Quarter 2024 Results / Half-Year Financial Report
Bayer Q2 2024 Media Update
Modest Performance in Challenging Agricultural Market Environment – Group outlook confirmed
- Group sales at 11.144 billion euros (Fx & portfolio adj. plus 3.1 percent)
- EBITDA before special items declines to 2.111 billion euros (minus 16.5 percent), impacted by currency headwinds
- Crop Science posts slight increase in sales and sharp fall in earnings
Pharmaceuticals and Consumer - Health report higher sales (Fx & portfolio adj.) and lower earnings
- Core earnings per share at 0.94 euros (minus 23.0 percent)
- Net income at minus 34 million euros
- Free cash flow at 1.273 billion euros
- Good progress on strategic priorities – advances in innovation, especially in the Pharmaceuticals Division